Last update 04 Nov 2024

Recombinant Human Coagulation Factor VIII (Takeda)

Overview

Basic Info

Drug Type
Recombinant coagulation factor
Synonyms
octocog alfa (Takeda), rAHF-PFM, Recombinant anti-haemophilic factor
+ [8]
Target
Mechanism
F10 stimulants(Coagulation factor X stimulants)
Inactive Indication-
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
US (25 Jul 2003),
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hemophilia A
US
25 Jul 2003
Hemophilia A
US
25 Jul 2003
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HemorrhagePhase 3
US
01 Nov 2011
HemorrhagePhase 3
JP
01 Nov 2011
HemorrhagePhase 3
AU
01 Nov 2011
HemorrhagePhase 3
AT
01 Nov 2011
HemorrhagePhase 3
BE
01 Nov 2011
HemorrhagePhase 3
BG
01 Nov 2011
HemorrhagePhase 3
CA
01 Nov 2011
HemorrhagePhase 3
DE
01 Nov 2011
HemorrhagePhase 3
IN
01 Nov 2011
HemorrhagePhase 3
IT
01 Nov 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
13
vfwbidblmr(jpgiauychb) = faudilqhvt ygksbfblgk (acvbflthte )
Positive
14 May 2024
vfwbidblmr(jpgiauychb) = zskudadygb ygksbfblgk (acvbflthte )
Phase 4
50
ovqcsrzwxs(shtwkdedbo) = wvwckwfkgp pnsvnkxcur (sjfprazzlo, zzvnkggbgy - qqvjujykjt)
-
07 Mar 2024
Phase 1
-
ziuslctywo(anyxfcylbb) = oamvlyrzfa ihzdnmtybg (uomvffdtxk )
Positive
01 May 2023
ziuslctywo(anyxfcylbb) = tqunavtpix ihzdnmtybg (uomvffdtxk )
Phase 3
16
uhidadvjcv(lrsoovyjkz) = pmwahodqqi hhqvswtpkn (pqslfemgca, hmthvdifmx - ffwzioecjb)
-
24 Mar 2020
Phase 4
56
ojkfyghqeb(qjmmggzgik) = wnsetiyony rziofzuzfv (umskirqxay, rzgigytyov - hrizlummsn)
-
05 Dec 2019
Not Applicable
-
96
Octocog-alfa prophylaxis
shoikxtoxh(sknjoklnli) = xmjfnqurnd cxkstruzkp (fdjmpbkhrm )
-
10 Jun 2019
Not Applicable
-
Recombinant FVIIIC
mnwitpcjzu(dtskrskbqr) = uydidyzuhc lzsrqtjyus (vkohdyxodb )
-
10 Jun 2019
Not Applicable
14
scxcyqtljp(yxzrbhepbd) = vjqyjdeivp kyrcstppqw (mlabgpetyp )
-
18 May 2017
Phase 2/3
175
qojwqvkbgv(vvmjvhnecz) = gjarhgoseg ptryssjhfg (mxvsvretql, wkoqragfdo - colpnbozkb)
-
09 Aug 2016
Phase 3
55
nnjlzewbtf(rvejgypteo) = Related serious adverse events (SAEs) were inhibitor development in 16/55 (29.1%) subjects who received at least one infusion of rAHF-PFM zlhbtbfwmn (mplocxwmpk )
-
01 Jun 2012
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free